



**Contact:**

Anthony Recupero, Ph.D.  
Vice President, Business Development  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

**MaxCyte To Be Sponsor and Featured Speaker at the Facilitate Cell and Gene Therapy Forum 2006**

**Gaithersburg, MD, January 25, 2006** – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces Madhusudan V. Peshwa, Ph.D., Vice President Research and Development, will be speaking at the Facilitate Cell and Gene Therapy Forum in Baltimore, Maryland, on Monday, January 30, 2006, at 3:05 PM. Dr. Peshwa's presentation entitled "Overcoming the technical and regulatory hurdles in the preclinical to clinical transition for cellular therapeutics", will discuss the application of a robust, scaleable, GMP compliant, closed system for non-viral gene delivery in the clinical development of an engineered tumor vaccine product for treatment of B-cell Chronic Lymphocytic Leukemia.

**About MaxCyte**

MaxCyte Inc. is a clinical stage company developing cell-based therapeutics primarily in the areas of oncology and regenerative medicine. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. The company also offers its unparalleled, customizable flow based cell loading technology to partners who take advantage of its advanced capabilities for cell-based therapeutic development and biotherapeutic (viral vector) manufacturing through licensing relationships. Partners are currently working to develop therapeutics for pulmonary, cardiovascular and infectious disease, cancer and regenerative medicine.

For more information, visit <http://www.maxcyte.com>.

*This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.*

###